ライフサイエンスコーパス: oncolytic virus

1 on-competent viruses that kill cancer cells (oncolytic viruses).

2 human cancer cells gives it potential as an oncolytic virus.

3 e promise both as a vaccine vector and as an oncolytic virus.

4 ll positioned for clinical development as an oncolytic virus.

5 ise both as an immunization vector and as an oncolytic virus.

6 er exogenous genes and replication-competent oncolytic viruses.

7 popular platform for the development of such oncolytic viruses.

8 e exploited by this virus, and perhaps other oncolytic viruses.

9 ntitumor therapies, including treatment with oncolytic viruses.

10 ul tool for developing novel tumor-selective oncolytic viruses.

11 m other viruses show promise as vaccines and oncolytic viruses.

12 ividual cancers vary in their sensitivity to oncolytic viruses.

13 great deal of progress in the development of oncolytic viruses.

14 h for new generations of efficiency-enhanced oncolytic viruses.

15 se reduction of doses of a relatively potent oncolytic virus, a finding with implications for the dev

16 eratively contribute towards mediating rapid oncolytic virus activity.

17 hampered by the relatively elevated doses of oncolytic viruses administered in animal models to achie

18 a cytopathic SV5 P/V mutant can serve as an oncolytic virus and that the oncolytic effectiveness of

19 is currently being considered as a clinical oncolytic virus and vaccine vector.

20 be used to study therapies involving various oncolytic viruses and chemotherapeutics, with the goal o

21 vides a new rationale for the combination of oncolytic viruses and chemotherapy.

22 to maximize the immunotherapeutic action of oncolytic viruses and clinical confirmation of a critica

23 subject to treatment with immunostimulatory oncolytic viruses and dendritic cell vaccines.

24 be adapted for ferrying ribonucleocapsids of oncolytic viruses and gene delivery vectors.

25 Understanding the interactions between oncolytic viruses and the innate immune system will faci

26 n comparison with other clinically evaluated oncolytic viruses and to PD-1 blockade, LCMV treatment s

27 ation that could be used in both vaccine and oncolytic virus applications.

28 Replicating oncolytic viruses are able to infect and lyse cancer cel

29 Oncolytic viruses are an active area of clinical researc

30 Oncolytic viruses are an innovative therapeutic strategy

31 Oncolytic viruses are being explored as a means to selec

32 Oncolytic viruses are genetically altered replication-co

33 Oncolytic viruses are genetically modified viruses that

34 Replication-competent herpes simplex oncolytic viruses are promising anticancer agents that p

35 Oncolytic viruses are promising therapeutics that can se

36 These studies indicate that oncolytic viruses are remarkably safe and more efficacio

37 Oncolytic viruses are used increasingly for cancer thera

38 Engineering an oncolytic virus armed with a CXCR4 antagonist represents

39 tacles, we have combined CAR-T cells with an oncolytic virus armed with the chemokine RANTES and the

40 we have generated immune cells infected with oncolytic viruses as a therapeutic strategy that can com

41 he rational design of the next generation of oncolytic viruses, as well as the discovery of efficacio

42 Oncolytic viruses based on adenovirus type 5 (Ad5) have

43 s aimed at promoting the optimum efficacy of oncolytic virus-based anticancer immunotherapies.

44 ating older approaches, such as vaccines and oncolytic virus-based treatments-are being investigated.

45 Newcastle disease virus (NDV) is an oncolytic virus being developed for the treatment of can

46 atment of disease as a vaccine vector and an oncolytic virus, but infection of the brain remains a co

47 proposed as tools to increase the potency of oncolytic viruses, but there is a need for mechanisms to

48 y therefore augment the therapeutic index of oncolytic viruses by inhibiting replication in normal ce

49 incorporation of fusogenic function into an oncolytic virus can significantly increase the potency o

50 ansductional retargeting strategies, whereby oncolytic viruses can be designed to selectively infect

51 oregional cancer therapeutic approaches with oncolytic viruses can lead to systemic anti-tumour immun

52 nt tumor cell killing makes it an attractive oncolytic virus candidate that may provide clinical bene

53 Replication-selective oncolytic viruses constitute a rapidly evolving and new

54 When these barriers are overcome, oncolytic viruses could enter the mainstream of clinical

55 One of the limitations observed with oncolytic viruses currently used in the treatment of sol

56 vector (Ad5) and constructed an HCC-specific oncolytic virus, CV890.

57 Oncolytic viruses designed to attack malignant cells can

58 an alternative region of dosing space (lower oncolytic virus dose, higher dendritic cell dose) for wh

59 However, when oncolytic virus doses were reduced (3 x 10(3) and 3 x 10

60 -FH has significant advantages over MV as an oncolytic virus due to its higher viral yield, faster re

61 s a first step towards understanding spatial oncolytic virus dynamics, upon which more detailed inves

62 Both HP-NAP protein and oncolytic viruses encoding HP-NAP have been suggested as

63 ividual cancers vary in their sensitivity to oncolytic viruses, even when these cancers arise from th

64 ividual cancers vary in their sensitivity to oncolytic viruses, even when these cancers arise from th

65 t that intratumoral immunomodulation with an oncolytic virus expressing a rationally selected ligand

66 Oncolytic viruses expressing inert soluble marker polype

67 icular stomatitis virus (VSV) is a potential oncolytic virus for treating glioblastoma multiforme (GB

68 V) is currently being studied as a candidate oncolytic virus for tumor therapies due to its potent tu

69 ow the efficacy of systemically administered oncolytic viruses for the treatment of spontaneously ari

70 stomatitis virus have recently been used as oncolytic viruses for tumor therapies and are being deve

71 Since then, oncolytic viruses from five different species have been

72 his drug with a herpes simplex virus-2-based oncolytic virus (FusOn-H2) against Lewis lung carcinoma,

73 um iodide symporter (NIS) (VSV-mIFNbeta-NIS) oncolytic virus has significant antileukemia activity, w

74 Athough the clinical efficacy of oncolytic viruses has been demonstrated for local treatm

75 Oncolytic viruses have been tested against many carcinom

76 Replication-selective oncolytic viruses have emerged as a new treatment platfo

77 The antitumoral effects of oncolytic viruses have generally been limited by ineffic

78 eplication and propagation in tumor tissues, oncolytic viruses have had only limited antitumor effect

79 Clinical and/or preclinical studies on oncolytic viruses have revealed that the candidate virus

80 Oncolytic viruses hold promise for the treatment of canc

81 way to enhance the antitumor effects of this oncolytic virus in future clinical trials.

82 analyzed by PCR reveals the presence of the oncolytic virus in the brains, livers, spleens, kidneys,

83 Selective replication of oncolytic viruses in tumor cells provides a promising ap

84 them an advantage over interferon-sensitive oncolytic viruses in tumors showing residual interferon

85 icacy of talimogene laherparepvec (T-VEC; an oncolytic virus) in combination with ipilimumab (a cytot

86 Oncolytic viruses, including oncolytic herpes simplex vi

87 Recently, however, many oncolytic viruses, including reovirus, have been reporte

88 ptive transfer of normal T cells loaded with oncolytic virus into individuals with cancer would be te

89 ired immunity, as the antitumor effect of an oncolytic virus is mainly generated during the acute pha

90 VSV as an oncolytic virus is particularly appealing for its except

91 the presumed advantages for using VSV as an oncolytic virus is that human infections are rare and pr

92 The cancer-selective nature of some oncolytic viruses is based on the impaired innate immuni

93 ting of tumor cells by replication-competent oncolytic viruses is considered indispensable for realiz

94 fects either on the cancer patient or on the oncolytic virus itself if they are expressed at the wron

95 VEGF165 inhibitors with systemic delivery of oncolytic viruses leads to substantial regression and cu

96 The increased therapeutic potency of this oncolytic virus may be useful in the treatment of a wide

97 As such, selective replication-competent oncolytic viruses may be useful as a potential treatment

98 nate immune effector mechanisms triggered by oncolytic viruses may contribute to the clearance of bot

99 Yet off-target infections by oncolytic viruses may increase virus production, further

100 ence demonstrating the concept of a combined oncolytic virus-mediated tumor diagnosis and therapy sys

101 This new oncolytic virus (MGH2) displays increased antitumor effi

102 Therefore, effective replication of HSV oncolytic viruses might be limited to a subpopulation of

103 In particular, an oncolytic virus must be resistant to the inhibition of D

104 ancer stemlike cells, cell cycle regulation, oncolytic viruses, new radiotherapy techniques, and immu

105 This study examined the behavior of two oncolytic viruses, NV1020 and G207, during liver regener

106 Oncolytic viruses obliterate tumor cells in tissue cultu

107 Oncolytic viruses offer an approach to destroy tumors by

108 Oncolytic viruses offer the attractive therapeutic combi

109 VSV is one oncolytic virus out of an arsenal of potential candidate

110 Drug Administration approval of immunogenic oncolytic virus (OV) has opened a new era in the treatme

111 herapeutic outcomes may be achieved by using oncolytic virus (OV) in combination with a potent immune

112 Farrar et al demonstrate that modifying an oncolytic virus (OV) so that it produces excess protein

113 Oncolytic virus (OV) therapies of cancer are based on th

114 Oncolytic virus (OV) therapy has emerged as a novel tool

115 ng VSV attachment and replication.IMPORTANCE Oncolytic virus (OV) therapy is an anticancer approach t

116 es of a hypoxia-regulated, prostate-specific oncolytic virus (OV) to prostate tumors.

117 and cancer cells leads to enhanced growth of oncolytic virus (OV)-based therapeutics.

118 icular stomatitis virus (VSV) is a promising oncolytic virus (OV).

119 Oncolytic viruses (OV) and ultrasound-enhanced drug deli

120 As cancer treatment tools, oncolytic viruses (OV) have yet to realize what some see

121 We have shown that oncolytic viruses (OV) injected into intracranial glioma

122 Oncolytic viruses (OV) preferentially kill cancer cells

123 Oncolytic viruses (OVs) are emerging as important agents

124 Oncolytic viruses (OVs) are promising therapeutics that

125 Clinical trials are testing oncolytic viruses (OVs) as therapies for cancer.

126 ng immunoshielding agents that could protect oncolytic viruses (OVs) from neutralizing antibodies (nA

127 , but antibody neutralization of circulating oncolytic virus particles remains a formidable barrier.

128 Oncolytic viruses pose many questions in their use in ca

129 illing, promotion of local immune responses, oncolytic virus production, and prodrug activation schem

130 Oncolytic viruses replicate selectively in tumor cells a

131 Oncolytic virus replication at a tumor site may not be a

132 ide and CPT-11 does not significantly affect oncolytic virus replication.

133 As such, oncolytic viruses represent a promising cancer-specific

134 elatively potent herpes simplex virus type 1 oncolytic virus (rQNestin34.5) produces 45% survivors at

135 Oncolytic viruses selectively lyse tumor cells, disrupt

136 RI) system to direct macrophages carrying an oncolytic virus, Seprehvir, into primary and metastatic

137 Implications for the initial dynamics of oncolytic virus spread through tumors are discussed.

138 e preclinical studies, melanin overproducing oncolytic virus strains might be used in clinical trials

139 Oncolytic viruses such as vesicular stomatitis virus (VS

140 s being developed presently as a therapeutic oncolytic virus [talimogene laherparepvec (T-VEC)].

141 the state of current research on the use of oncolytic viruses targeted to stem cells as a potential

142 Our results suggest that ZIKV is an oncolytic virus that can preferentially target GSCs; thu

143 utant HSV1716 is a conditionally replicating oncolytic virus that selectively replicates in and lyses

144 Currently, no oncolytic viruses that are able to kill only tumor cells

145 Oncolytic viruses that can destroy cancer cells have bee

146 of new therapeutic genes into the genome of oncolytic viruses that could not have been tested otherw

147 We explored the use of oncolytic virus therapy against glioblastoma with Zika v

148 this approach might increase the efficacy of oncolytic virus therapy and to identify gaps in knowledg

149 These data indicate that the use of VSV for oncolytic virus therapy for prostate tumors may require

150 Oncolytic virus therapy is being evaluated in clinical t

151 Mathematical modeling of oncolytic virus therapy is often limited by the fact tha

152 A major challenge to oncolytic virus therapy is that individual cancers vary

153 One of the several impediments to effective oncolytic virus therapy of cancer remains a lack of tumo

154 s recombinant vaccinia vSP shows promise for oncolytic virus therapy.

155 to the burgeoning fields of cancer-killing (oncolytic) virus therapy with vaccinia virus (VACV).

156 nlike our previous findings with less potent oncolytic viruses, though, the preadministration of cycl

157 randomized trial to evaluate addition of an oncolytic virus to a checkpoint inhibitor.

158 human T lymphocytes effectively deliver live oncolytic virus to human multiple myeloma cells, thus au

159 T cell trafficking in order to chaperone an oncolytic virus to lymphoid organs harboring metastatic

160 s, thus augmenting GVM by transfer of active oncolytic virus to residual cancer cells.

161 e injection site has limited the capacity of oncolytic viruses to achieve consistent therapeutic resp

162 diation interacts with replication-competent oncolytic viruses to enhance viral replication and tumor

163 adenovirus from the mechanism used by other oncolytic viruses to induce autophagy and provides a new

164 method to overcome this challenge is to use oncolytic viruses to induce secondary antitumor immune r

165 r than completely eliminating the ability of oncolytic viruses to infect and lyse normal cells could

166 A workshop "Targeting Oncolytic Viruses to Tumor Stem Cells," organized by the

167 inistering a single dose of TGFbeta prior to oncolytic virus treatment of glioblastoma can transientl

168 nificantly enhanced both animal survival and oncolytic virus tumor distribution and also reduced tumo

169 mide did not enhance this survival or affect oncolytic virus tumor distribution and tumor volume.

170 Oncolytic viruses used for gene therapy have been geneti

171 ers that can bind noncovalently to an intact oncolytic virus, vaccinia virus (VACV), which can select

172 e enhanced functional studies, generation of oncolytic virus vectors, development of delivery platfor

173 ugh intravascular administration may deliver oncolytic viruses/vectors to each of these tumors, its e

174 Here, we took a promising oncolytic virus, vesicular stomatitis virus (VSV), and t

175 is work, we selected DNA aptamers against an oncolytic virus, vesicular stomatitis virus (VSV), to pr

176 Replication-selective oncolytic viruses (virotherapeutics) are being developed

177 ning of the first clinical trial in which an oncolytic virus was administered to cancer patients.

178 immune responses, to enhance the activity of oncolytic viruses, we evaluated the effect of coadminist

179 Unlike many other oncolytic viruses, we found no evidence that impairment

180 dentify the effector mechanisms activated by oncolytic viruses, we investigated inhibition of prolife

181 The murine oncolytic viruses were successfully armed with murine gr

182 Conditionally replicating (oncolytic) viruses, which selectively replicate in tumor

183 e cytokine IL15, reasoning that the modified oncolytic virus will both have a direct lytic effect on

184 s designed to enhance the potency of current oncolytic viruses will likely increase their chance of c

185 Here, we report an approach to arm an oncolytic virus with CD40 ligand (CD40L) to stimulate be

186 rotein and Fcy::Fur provides a highly potent oncolytic virus with improved capabilities for local tum

187 novirus is a promising replication-selective oncolytic virus with targeting specificity for EBV-assoc

188 Our data demonstrate that combining an oncolytic virus with tumor-targeting immune checkpoint m

189 ons may allow for the generation of modified oncolytic viruses with greater selective tumor cell repl

190 mathematical framework for assessing whether oncolytic viruses with reduced tumor-specificity can mor

191 t, much effort is being focused on combining oncolytic viruses with standard treatment modalities suc

192 Using replication-competent HSV-1 oncolytic viruses with thymidine kinase (TK) under contr